Les essais en cours

COLORECTAL

• Prodige 90 :PREDIR-NEOREC Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients: a Randomized Phase II Trial Phase II Randomized Study Non-comparative - Multicenter
  https://clinicaltrials.gov/study/NCT06762405?term=PREDIR-NEOREC&rank=1
  
  
• PREMICES : Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for Patients With Mismatch Repair-deficient or Microsatellite Instability-high (dMMR/MSI-H) Localized Colon Cancer: a Randomized GERCOR G-109 PRODIGE 84 PREMICES Phase II Trial
  https://clinicaltrials.gov/study/NCT06646445?term=premices&rank=1
  
  
• CIRCULATE PRODIGE 70 : CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
  https://clinicaltrials.gov/study/NCT04120701?term=circulate&rank=3
  
  
• FUDOSE: ihydropyrimidine Dehydrogenase (DPD) Phenotype-guided Dose Individualization of Fluoropyrimidine-based Chemotherapy in DPD Deficient Patients With Gastrointestinal Cancers
  https://clinicaltrials.gov/study/NCT06475352?term=fudose&rank=1
  
  
• (OrigAMI-2) :A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  https://clinicaltrials.gov/study/NCT06662786?term=OrigAMI-2&rank=1 Colorectal Cancer
  
  
• An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
  https://clinicaltrials.gov/study/NCT05253651?term=MOUNTAINEER-03&rank=1
  
  
• ONO-4578-10 : A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
  https://clinicaltrials.gov/study/NCT06948448?term=ONO-4578-10&rank=1
  
  
• POCHI : Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
  https://clinicaltrials.gov/study/NCT04262687?term=POCHI&rank=1
  
  
• TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial
  https://clinicaltrials.gov/study/NCT06245356?term=TRIFLUOX-DP&rank=1
  
  
• MOIO : Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO
  https://clinicaltrials.gov/study/NCT05078047?term=MOIO&rank=1
  
  
• EMBOLD PanTumor-101 : A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
  https://clinicaltrials.gov/study/NCT06551142?term=GSK%20EMBOLD%20&rank=2
  
  
• REPROGRAM-02 : Induction Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin Followed by Chemotherapy in Second Line Metastatic Colorectal Cancer Carcinoma An Open-label Randomized Phase II-III Study
  https://clinicaltrials.gov/study/NCT05462613?term=REPROGRAM-02&rank=1
  
  
• TARGETMONITO : Dosing of Various Multi Kinases Inhibitors Plasma Concentrations for Patients Treated for Their Advanced Digestive Cancer, With the Aim to Determine the Best Optimal Dose for Each Treatment, in the Future
  https://clinicaltrials.gov/study/NCT05443087?term=TARGETed%20therapy%20drug%20MONITOring%20in%20DIGestive%20oncology&rank=1
  
  
• NIMBUS 9216-101 : A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair
  https://clinicaltrials.gov/study/NCT06898450?term=9216-101&rank=1
  
  
• NIPIRESCUE : Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy: An Open-label Phase II GERCOR Trial (NIPIRESCUE)
  https://clinicaltrials.gov/study/NCT05310643?term=NIPIRESCUE&rank=1
  

PANCREAS

• DOVIPA : a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 With Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer
  https://clinicaltrials.gov/study/NCT06757244?term=DOVIPA&rank=1
  
  
• Pan-MSI-ACSE : Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
  https://clinicaltrials.gov/study/NCT06333314?term=Pan-MSI&rank=2
  
  
• MOIO : Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO
  https://clinicaltrials.gov/study/NCT05078047?term=MOIO&rank=1
  
  
• NIMBUS 9216-101 : A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair
  https://clinicaltrials.gov/study/NCT06898450?term=9216-101&rank=1
  

GASTRIQUE

• BIG : Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II
  https://clinicaltrials.gov/study/NCT06253611?term=BIG%20gercor&rank=1
  
  
• LUCERNA : A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
  https://clinicaltrials.gov/study/NCT06901531?term=LUCERNA&rank=1
  
  
• Destiny-Gastric05 : A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer
  https://clinicaltrials.gov/study/NCT06731478?term=DESTINY-gastric05&rank=1
  
  
• Pan-MSI-ACSE : Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
  https://clinicaltrials.gov/study/NCT06333314?term=Pan-MSI&rank=2
  
  
• TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial
  https://clinicaltrials.gov/study/NCT06245356?term=TRIFLUOX-DP&rank=1
  
  
• MOIO : Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO
  https://clinicaltrials.gov/study/NCT05078047?term=MOIO&rank=1
  
  
• IDeate-Esophageal01 : A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
  https://clinicaltrials.gov/study/NCT06644781?term=IDeate-Esophageal01&rank=1
  
  
• NIMBUS 9216-101 : A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair
  https://clinicaltrials.gov/study/NCT06898450?term=9216-101&rank=1

VOIES BILIAIRES

• SAFIR-ABC10 : Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
  https://clinicaltrials.gov/study/NCT05615818?term=PRODIGE%2078&rank=1
  
  
• NIMBUS 9216-101 : A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair
  https://clinicaltrials.gov/study/NCT06898450?term=9216-101&rank=1

GIST ET NEURO-ENDOCRINE

• NEONEC : Phase II Study to Evaluate the Efficacy of 12-month Neoadjuvant Chemotherapy in Terms of Disease-free Survival in Patients With Localized Digestive Neuroendocrine Carcinomas
  https://clinicaltrials.gov/study/NCT04268121?term=neonec&rank=1
  
  
• FOLFIRINEC : Folfirinox Versus Platinum - Etoposide as First Line Chemotherapy for Metastatic Grade 3 Poorly Differentiated Neuroendocrine Carcinoma of Gastro Entero Pancreatic and Unknown Primary Associated With Molecular Profiling for Therapeutic Targets & Predictive Biomarkers Identification
  https://clinicaltrials.gov/study/NCT04325425?term=FOLFIRINEC%20&rank=1
  
  
• Pan-MSI-ACSE : Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
  https://clinicaltrials.gov/study/NCT06333314?term=Pan-MSI&rank=2
  
  
• TARGETMONITO : Dosing of Various Multi Kinases Inhibitors Plasma Concentrations for Patients Treated for Their Advanced Digestive Cancer, With the Aim to Determine the Best Optimal Dose for Each Treatment, in the Future
  https://clinicaltrials.gov/study/NCT05443087?term=TARGETed%20therapy%20drug%20MONITOring%20in%20DIGestive%20oncology&rank=1